PCI BIOTECH HOLDING ASA (PCIB.OL) Stock Price, Forecast & Analysis
Europe - OSL:PCIB - NO0010405640 - Common Stock
PCIB.OL Key Statistics, Chart & Performance
The current stock price of PCIB.OL is 0.28 NOK. In the past month the price decreased by -20%. In the past year, price decreased by -78.46%.
PCIB.OL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 71.89 | 47.36B | ||
| ARGX.BR | ARGENX SE | 72.88 | 48.01B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.63B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.33B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.33B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.80B | ||
| 5CV.DE | CUREVAC NV | 5.24 | 1.03B | ||
| NANO.PA | NANOBIOTIX | N/A | 876.56M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| IVA.PA | INVENTIVA SA | N/A | 494.46M | ||
| FYB.DE | FORMYCON AG | N/A | 366.65M | ||
| VLA.PA | VALNEVA SE | N/A | 332.16M |
Related stock screener links
About PCIB.OL
Company Profile
PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo and currently employs 7 full-time employees. The company went IPO on 2008-06-18. The firm is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. The company is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.
Company Info
PCI BIOTECH HOLDING ASA
Ullernchauseen 64
Oslo OSLO NO
Employees: 5
Phone: 4767115400
PCI BIOTECH HOLDING ASA / PCIB.OL FAQ
What does PCIB do?
PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo and currently employs 7 full-time employees. The company went IPO on 2008-06-18. The firm is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. The company is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.
Can you provide the latest stock price for PCI BIOTECH HOLDING ASA?
The current stock price of PCIB.OL is 0.28 NOK. The price increased by 1.08% in the last trading session.
Does PCIB stock pay dividends?
PCIB.OL does not pay a dividend.
How is the ChartMill rating for PCI BIOTECH HOLDING ASA?
PCIB.OL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of PCI BIOTECH HOLDING ASA (PCIB.OL) based on its PE ratio?
PCI BIOTECH HOLDING ASA (PCIB.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.44).
Can you provide the number of employees for PCI BIOTECH HOLDING ASA?
PCI BIOTECH HOLDING ASA (PCIB.OL) currently has 5 employees.
What is the market capitalization of PCIB stock?
PCI BIOTECH HOLDING ASA (PCIB.OL) has a market capitalization of 10.45M NOK. This makes PCIB.OL a Nano Cap stock.
PCIB.OL Technical Analysis
PCIB.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PCIB.OL. While PCIB.OL has a great health rating, there are worries on its profitability.
PCIB.OL Financial Highlights
Over the last trailing twelve months PCIB.OL reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 19.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -88.63% | ||
| ROE | -131.18% | ||
| Debt/Equity | 0 |